Get started
Author

Eugene K. Cha

Observed names: Cha, Eugene K, Eugene K Cha, Eugene K. Cha A, K. Eugene
ORCID: 0000-0002-8807-2353
Observed ORCID: 0000-0002-8807-2353
OpenAlex ID: A5077948458
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
2016 · Hikmat A Al-Ahmadie, Gopa Iyer, et al. · Nature Genetics · 200
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
2023 · Jonathan A. Coleman, Wesley Yip, et al. · Journal of Clinical Oncology · 112
PDF
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
2022 · Samuel A. Funt, Michael Lattanzi, et al. · Journal of Clinical Oncology · 104
PDF
Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy
2018 · Eugene K. Cha, John P. Sfakianos, et al. · British Journal of Urology · 32
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
2022 · Nima Almassi, Karissa Whiting, et al. · JCO Precision Oncology · 28
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy
2021 · Nima Almassi, Emily A. Vertosick, et al. · British Journal of Urology · 26
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
2024 · Andrew T. Lenis, Karissa Whiting, et al. · JCO Precision Oncology · 6
PDF
Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device
2018 · Mazyar Ghanaat, Andrew G. Winer, et al. · Urology · 6
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · Brendan J. Guercio, Eugene J. Pietzak, et al. · Clinical Cancer Research · 1
PDF
Comprehensive clinical and genomic analysis of early-onset cancer of the bladder and upper urinary tract
2026 · Hong Truong, Jordan Eichholz, et al. · JNCI Journal of the National Cancer Institute
Supplemental Figures from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · Brendan J. Guercio, Eugene J. Pietzak, et al.
Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · Brendan J. Guercio, Eugene J. Pietzak, et al.
Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · Brendan J. Guercio, Eugene J. Pietzak, et al.
Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · Brendan J. Guercio, Eugene J. Pietzak, et al.
The efficacy of BCG Tice and BCG Connaught in a cohort of 2099 T1G3 non-muscle invasive bladder cancer patients
2016 · J.A. Witjes, Dalbagni, et al.
Works count: 17
Citation count: 515
H-index: 6
I10-index: 6
Year
Topic
Type